

Reference number
1710-H

SPECIALTY QUANTITY LIMIT PROGRAM

SOMATULINE DEPOT (lanreotide)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Somatuline (lanreotide) Depot Inj 60 mg/0.2 mL	60 mg per 28 days	Acromegaly: <ul style="list-style-type: none"> • Recommended starting dose is 90 mg every 4 weeks for 3 months. Adjust thereafter based on GH and/or IGF-1 levels. • Dose range is 60 mg to 120 mg every 4 weeks. Moderate and severe renal and hepatic impairment: Initial dose is 60 mg every 4 weeks for 3 months. Adjust thereafter based on GH and/or IGF-1 levels. Gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome: 120 mg every 4 weeks
Somatuline (lanreotide) Depot Inj 90 mg/0.3 mL	90 mg per 28 days	
Somatuline (lanreotide) Depot Inj 120 mg/0.5 mL	120 mg per 28 days	

III. REFERENCES

1. Somatuline Depot [package insert]. Basking Ridge, NJ: Ipsen Pharmaceuticals, Inc.; December 2018.